2204. Pathogen Co-infections and Trends in Influenza-like Illness in PAIVED. (15th December 2022)

• Record Type: Journal Article
• Authors: Richard, Stephanie A; Schofield, Christina; Collins, Limone; Spooner, Christina; Seshadri, Srihari; Ganesan, Anuradha; Campbell, Wesley R; Hrncir, David; Lalani, Tahaniyat; Warkentien, Tyler; Mende, Katrin; Markelz, Ana E; Berjohn, Catherine M; McClenathan, Bruce; Modi, Jitendrakumar; Williams, Alan; Burgess, Timothy; Colombo, Rhonda E
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1823
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: The Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (DoD) (PAIVED) is a multicenter, multiservice study assessing influenza vaccine effectiveness in active-duty service members, retirees, and dependents. In its fourth season (2021/22), PAIVED offers a unique opportunity to examine influenza-like illness (ILI) trends prior to and during the COVID-19 pandemic in a prospectively followed, well-defined cohort. Methods: Over the past 4 influenza seasons, PAIVED has enrolled DoD beneficiaries who were randomized to receive egg-based, cell-based, or recombinant-derived influenza vaccine. Participants provided some basic demographic information and were then sent a weekly text or email that inquired about ILI symptoms, defined as 1) having cough or sore throat, plus 2) feeling feverish/having chills or having body aches/fatigue. Participants with ILI completed a daily symptom diary for one week and submitted a nasal swab for PCR-based pathogen detection. Table 1. Demographic characteristics of PAIVED participants over four seasons Figure 1. Percent of PAIVED participants with influenza-like illness, SARS-CoV-2, influenza, and rhinovirus identified in swab samples collected over four seasons. Results: Over the 4 seasons, 15, 449 participants were followed for ILI (Table 1) with 3, 407 participants reporting a total of 3, 985 ILIs. For the 2021/22 season, ILI reports peaked in January (Figure 1). Overall, 4.7% of episodes had more than one pathogen identified (Table 2). Among the 122 coinfections identified to date, most were coinfections with rhinoviruses (91/122, 75%), including rhinovirus coinfections with seasonal coronaviruses (29, 24%), metapneumovirus (18, 15%), SARS-CoV-2 (17, 14%), and influenza (14, 11%). SARS-CoV-2 and influenza were found together in one sample. The lab data will continue to be processed for the current season (2021/22). Table 2. Pathogens identified in PAIVED nasal swabs over four seasons Conclusion: ILI rates were lowest during the third year (2020/21), consistent with national influenza surveillance reports of influenza and outpatient ILI activity, suggesting that measures taken to reduce transmission of SARS-CoV-2 reduced the spread of other respiratory viruses. The emergence of the SARS-CoV-2 omicron variant in December 2021 was associated with higher ILI rates. Among those individuals for whom a sample was collected, coinfections were highest in 2018/19. Data collection and specimen analysis are ongoing for 2021/22. Disclosures: Jitendrakumar Modi, MD, GlaxoSmithKline: I am a paid speaker for GSK. I do not speak for their flu brand. Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.